Relationship Between ABCF2 Expression and Response to Chemotherapy or Prognosis in Clear Cell Adenocarcinoma of the Ovary
Relationship Between ABCF2 Expression and Response to Chemotherapy or Prognosis in Clear Cell Adenocarcinoma of the Ovary
复制标题
DOI：
10.1111/igc.0b013e3181a835fc
复制
发表时间：
2010-07-01
影响因子：
4.8
通讯作者：
Aoki, Daisuke
中科院分区：
文献类型：
--
作者：
Tsuda, Hiroshi;Ito, Kiyoshi;Aoki, Daisuke
目的：本研究的目的是评估ABCF2（三磷酸腺苷结合盒超家族F2）蛋白表达与卵巢透明细胞腺癌（CCC）患者化疗反应和预后的关系。方法：以165例CCC患者为研究对象，采用免疫组化染色法检测细胞质中ABCF2的表达。所有患者均接受以铂为基础的初始化疗，随后进行初始手术。结果：165例患者中有118例（71.5%）检测到三磷酸腺苷结合盒超家族F2的表达，与年龄和临床分期无关。38例可测量疾病患者化疗有效率为47.3%（18/38）。无ABCF2表达的患者有效率高于有ABCF2表达的患者；但差异不显著（66.7% vs 34.8%, P = 0.096）。abcf2阳性和abcf2阴性患者的总生存期无显著差异（中位生存时间，1175天vs 1257天；P = 0.24）。结论：三磷酸腺苷结合盒超家族F2蛋白在卵巢CCC中高表达，但表达与年龄、临床分期、化疗反应、预后无关。
Objectives: The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphate-binding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary.Methods: One hundred sixty-five patients with CCC were studied, and cytoplasmic ABCF2 expression was detected by immunohistochemical staining. All patients underwent platinum-based primary chemotherapy followed by primary surgery.Results: Adenosine triphosphate-binding cassette superfamily F2 expression was detected in 118 (71.5%) of 165 patients and was not related to age or clinical stage. The response rate to chemotherapy in 38 patients with measurable disease was 47.3% (18/38). The response rate tended to be higher in patients without ABCF2 expression than in those with ABCF2 expression; however, this difference was not significant (66.7% vs 34.8%, P = 0.096). There was no significant difference in overall survival between ABCF2-positive and ABCF2-negative cases (median survival time, 1175 vs 1257 days; P = 0.24).Conclusions: Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.